Apixaban versus warfarin for primary thromboprophylaxis in patients with multiple myeloma undergoing immunomodulatory treatment. This is an ASCO Meeting Abstract from the 2024 ASCO Annual Meeting I.
Immunotherapy has revolutionized cancer treatment by harnessing the power of T cells to attack tumors. But, even when these treatments are successful, scientists often struggle to understand exactly ...
As of April 2025, four CD19-directed chimeric antigen receptor (CAR)-T therapies and three CD20-targeting bispecific antibodies (BsAbs) have been US Food and Drug Administration (FDA) approved for the ...
Please provide your email address to receive an email when new articles are posted on . A “complete eradication” of B cells with chimeric antigen receptor T-cell therapy is responsible for the ...
Renier Brentjens, MD, PhD, one of the pioneers in the development of chimeric antigen receptor (CAR) T-cell therapy, is poised to see the technology take its next big leap, with researchers testing ...
Chimeric antigen receptor (CAR) T-cell therapy has transformed the treatment of refractory or relapsed leukemia and hematologic malignancies, particularly over the past decade. Despite its ...
CU Anschutz researchers uncovered a link between a type of mucosal immune cell and gut inflammation, finding that the cells ...
The risk of second tumors after chimeric antigen receptor (CAR) T-cell therapy, especially the risk of T-cell neoplasms related to viral vector integration, is an emerging concern. A total of 724 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback